Related Experiment Video

Updated: Jul 20, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Diabetes does not influence treatment decisions regarding revascularization in patients with stable coronary artery

Arno Breeman1, Michel E Bertrand, Jan Paul Ottervanger

  • 1Department of Cardiology, Isala Klinieken, Zwolle, the Netherlands.

Diabetes Care
|August 29, 2006
PubMed

Insights

Diabetes status does not influence treatment decisions for coronary revascularization in stable angina patients. Furthermore, diabetes was not linked to worse outcomes after procedures like percutaneous coronary intervention or coronary artery bypass surgery.

Area of Science:

  • Cardiology
  • Diabetology
  • Clinical Research

Background:

  • Stable angina affects millions, with treatment decisions often involving revascularization.
  • Diabetes is a significant comorbidity impacting cardiovascular health and treatment choices.
  • Understanding the interplay between diabetes, revascularization strategies, and patient outcomes is crucial.

Purpose of the Study:

  • To investigate if diabetes influences the choice between percutaneous coronary intervention (PCI) and coronary artery bypass surgery (CABG) in stable angina.
  • To determine if diabetes status has prognostic implications for patients undergoing coronary revascularization.

Main Methods:

  • Analysis of 2,928 stable angina patients from the Euro Heart Survey on Coronary Revascularization.
  • Multivariable analyses to assess the relationship between diabetes, treatment selection, and 1-year outcomes.

Main Results:

  • Diabetes was present in 20% of patients and associated with more extensive coronary disease.
  • Treatment decisions for revascularization (PCI vs. CABG) were not significantly influenced by diabetes status overall.
  • Specific subgroups, like those with mild heart failure, showed some influence of diabetes on treatment decisions.
  • Diabetes was not associated with increased risk of death or major cardiovascular events at 1 year post-revascularization.

Conclusions:

  • Diabetes does not appear to influence treatment decisions for coronary revascularization (PCI or CABG) in stable angina patients.
  • The presence of diabetes is not linked to a poorer prognosis in these patients following revascularization.
Abstract

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Angina II: Classification01:27

Angina II: Classification

Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...